Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RYTM – Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals, Inc.
RYTM
$99.67
Name : Rhythm Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,620,090,368.00
EPSttm : -3.01
finviz dynamic chart for RYTM
Rhythm Pharmaceuticals, Inc.
$99.67
0.16%
$0.16

Float Short %

8.5

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

0.03

EPS Last/This Y

1.39

EPS This/Next Y

1.05

Price

99.81

Target Price

118.36

Analyst Recom

1.13

Performance Q

12.17

Relative Volume

0.61

Beta

2.13

Ticker: RYTM




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08RYTM99.780.200.0512864
2025-09-09RYTM101.460.210.2213558
2025-09-10RYTM100.270.210.4713577
2025-09-11RYTM97.920.211.1113575
2025-09-12RYTM96.20.210.2013624
2025-09-15RYTM95.690.200.3113902
2025-09-16RYTM95.550.200.3314022
2025-09-17RYTM96.10.20042771599658314033
2025-09-18RYTM98.60.200.0014037
2025-09-19RYTM96.140.190.0114946
2025-09-22RYTM98.950.390.057536
2025-09-23RYTM98.650.380.397647
2025-09-24RYTM96.980.380.968022
2025-09-25RYTM99.170.381.428079
2025-09-26RYTM99.180.380.018077
2025-09-29RYTM100.280.380.018088
2025-09-30RYTM1010.351.308591
2025-10-01RYTM100.070.355.258608
2025-10-02RYTM97.140.362.418614
2025-10-03RYTM99.010.360.508631
2025-10-06RYTM97.890.360.448652
2025-10-07RYTM99.830.360.478660
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08RYTM99.77-0.5- -2.95
2025-09-09RYTM101.43-0.5- -2.95
2025-09-10RYTM100.25-0.5- -2.95
2025-09-11RYTM97.92-0.5- -2.95
2025-09-12RYTM96.15-0.5- -2.95
2025-09-15RYTM96.03-0.5- -2.95
2025-09-16RYTM95.51-0.5- -2.95
2025-09-17RYTM96.14-0.5- -2.95
2025-09-18RYTM98.53-0.5- -2.95
2025-09-19RYTM96.11-0.5- -2.95
2025-09-22RYTM99.00-0.5- -2.95
2025-09-23RYTM98.67-0.5- -2.95
2025-09-24RYTM96.96-0.5- -2.95
2025-09-25RYTM99.14-0.5- -2.95
2025-09-26RYTM99.16-0.5- -2.95
2025-09-29RYTM100.63-0.5- -2.95
2025-09-30RYTM101.04-0.5- -2.95
2025-10-01RYTM100.03-0.5- -2.95
2025-10-02RYTM97.25-0.5- -2.95
2025-10-03RYTM98.99-0.5- -2.95
2025-10-06RYTM97.90-0.5- -2.95
2025-10-07RYTM99.81-0.5- -2.95
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08RYTM-7.473.217.60
2025-09-09RYTM-7.473.217.60
2025-09-10RYTM-7.473.217.60
2025-09-11RYTM-7.473.218.08
2025-09-12RYTM-7.473.218.09
2025-09-15RYTM-7.333.278.09
2025-09-16RYTM-7.333.278.09
2025-09-17RYTM-7.333.278.09
2025-09-18RYTM-7.333.278.09
2025-09-19RYTM-6.023.278.09
2025-09-22RYTM-6.023.278.09
2025-09-23RYTM-6.023.278.09
2025-09-24RYTM-6.023.278.09
2025-09-25RYTM-6.023.278.50
2025-09-26RYTM-6.023.278.50
2025-09-29RYTM-6.023.288.50
2025-09-30RYTM-6.023.288.50
2025-10-01RYTM-6.023.288.50
2025-10-02RYTM-6.023.288.50
2025-10-03RYTM-6.023.288.50
2025-10-06RYTM-6.023.568.50
2025-10-07RYTM-6.023.568.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.75

Avg. EPS Est. Current Quarter

-0.73

Avg. EPS Est. Next Quarter

-0.72

Insider Transactions

-6.02

Institutional Transactions

3.56

Beta

2.13

Average Sales Estimate Current Quarter

50

Average Sales Estimate Next Quarter

54

Fair Value

Quality Score

43

Growth Score

40

Sentiment Score

57

Actual DrawDown %

6.3

Max Drawdown 5-Year %

-92.1

Target Price

118.36

P/E

Forward P/E

PEG

P/S

42.43

P/B

P/Free Cash Flow

EPS

-3.02

Average EPS Est. Cur. Y​

-2.95

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-120.55

Relative Volume

0.61

Return on Equity vs Sector %

-166.3

Return on Equity vs Industry %

-152.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Rhythm Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 283
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading